News Focus
News Focus
icon url

golden flyer

05/14/20 12:29 PM

#273602 RE: Bill B #273601

been out for 2 hours the markets response was...…..yawn
icon url

rosemountbomber

05/14/20 12:33 PM

#273605 RE: Bill B #273601

Bill, not sure it is unless Du decision is reversed
icon url

circuitcity

05/14/20 12:33 PM

#273606 RE: Bill B #273601

Exactly, when I saw your post, I immediately check the sp, not really
icon url

Whalatane

05/14/20 12:56 PM

#273613 RE: Bill B #273601

Bill Thx for linking this presentation .
Very important info .
CABG is a very expensive procedure and even a straight forward revascularization probably costs around $20k ( including ER , Cath lab time ) .
This makes Vascepa a VERY cost effective medicine .


Quote:


For statin-treated patients with elevated triglycerides and increased cardiovascular risk, icosapent ethyl significantly reduced first and subsequent revascularizations compared with placebo. We are aware of no other non-LDL based therapy in the statin era that has been shown to reduce CABG in a blinded, randomized trial



Kiwi
icon url

Biobillionair

05/14/20 1:17 PM

#273621 RE: Bill B #273601

It is huge news and ICER needs to revisit the costs savings by reduced open heart CABG. The drug is an ICER A+ and significantly saves social overall health costs.

Every insurance provider should be forwarded this data ASAP.


BB